Accenture Invests in Ryght AI to Solve the $2.6 Billion Clinical Trial Problem

Clinical trials have been stuck for sometime. Researchers know how to design good studies but get stuck administratively. A drug candidate that shows promise in the lab still needs to find the right research sites, recruit patients, and manage complex protocols across global networks. This operational halt costs billions and delays treatments by years.

On December 11, Accenture announced an investment in Ryght AI, a platform that uses agentic AI to automate the three most painful steps in drug development like trial feasibility, site selection, and patient recruitment. The company built what it calls AI Site Twins, digital replicas of every clinical research site on the planet that capture historical performance, patient demographics, and operational data in real-time.

The firm had invested in 1910 Genetics (drug discovery), Turbine (cell simulation), and Earli (early cancer detection) before as well. But the Ryght AI investment signals something larger. Enterprise consulting firms are moving beyond advising on AI transformation. They're now investing directly in domain-specific AI platforms and bringing them to their client base at scale.

Drug development costs have gone up exponentially. According to Tufts Center for the Study of Drug Development, a new medication takes 10-15 years and $2.6 billion to bring to market. Clinical trials consume 50-60% of that cost and time. Within clinical trials, site selection and patient recruitment are the most painful steps, relying on spreadsheets, manual outreach, and educated guesses about which hospitals and clinics can actually enroll patients.